Abstract Objective To analyze the patterns and distribution of lymph node metastasis in patients with adenocarcinoma of the esophagogastric junction (AEG). Methods The pathological data of 393 patients with AEG from 2006 to 2009 were analyzed. The patterns and distribution of lymph node metastasis were analyzed in patients with different Siewert subtypes, depths of tumor invasion, and maximum diameters of the tumor, and the high-risk lymphatic drainage areas were investigated. Between-group comparison was performed by χ2 test. Results The metastatic rate and ratio of abdominal lymph nodes in AEG were 69.2% and 31.31%, respectively. The incidence rates of lymph node metastasis in the cardia, lesser curvature, left gastric artery, splenic artery, splenic hilum, mesenteric root, and abdominal aorta were the highest. The metastatic rate and ratio of mediastinal lymph nodes were 16.4% and 8.3%, respectively. The incidence rates of lymph node metastasis in the lower paraesophageal, esophageal hiatus, and superior diaphragmatic areas were the highest. Compared with Siewert type II and type III AEG, Siewert type I AEG had a significantly higher mediastinal lymph node metastatic rate (P=0.003) and a significantly lower abdominal lymph node metastatic ratio (P=0.002).The metastatic ratios of lymph nodes in multiple abdominal regions were higher in patients with stage T3+T4 AEG and a maximum tumor diameter of ≥6 cm than in the control group, while the metastatic ratios of mediastinal lymph nodes in groups with different maximum tumor diameters were similar. The metastatic ratios of lymph nodes in the greater curvature, hepatoduodenal ligament, and inferior diaphragmatic areas were lower than 10% in all groups. Conclusions In radiotherapy for AEG, the abdominal high-risk lymphatic drainage areas involve the cardia, lesser curvature, left gastric artery, splenic artery, splenic hilum, mesenteric root, and abdominal aorta, while the mediastinal high-risk lymphatic drainage areas involve the lower paraesophageal, esophageal hiatus, and superior diaphragmatic areas. In addition, the personalized target volume design should be based on the patterns of lymph node metastasis with different Siewert subtypes and clinical pathological characteristics.
Wang Jun,Zhang Yanjun,Liu Qing et al. The patterns of lymph node metastasis in adenocarcinoma of esophagogastric junction:a reference for target volume delineation in radical radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 367-370.
Wang Jun,Zhang Yanjun,Liu Qing et al. The patterns of lymph node metastasis in adenocarcinoma of esophagogastric junction:a reference for target volume delineation in radical radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 367-370.
[1] Siewert J,H lscher A,Becker K,et al. Cardia cancer:attempt at a therapeutically relevant classification[J].Chirurg,1987,58(1):25-32. [2] Jemal A,Murray T,Ward E,et al. Cancer statistics,2005[J].CA Cancer J Clin,2005,55(1):10-30. [3] Piso P,Werner U,Lang H,et al. Proximal versus distal gastric carcinoma-what are the differences?[J].Ann Surg Oncol,2000,7(7):520-525. [4] van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [5] Stahl M,Walz MK,Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J].J Clin Oncol,2009,27(6):851-856.DOI:10.1200/JCO.2008.17.0506. [6] Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.DOI:10.1200/JCO.2007.12.9593. [7] Pedrazzani C,de Manzoni G,Marrelli D,et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma[J].J Thorac Cardiovasc Surg,2007,134(2):378-385. [8] M nig SP,Baldus SE,Zirbes TK,et al. Topographical distribution of lymph node metastasis in adenocarcinoma of the gastroesophageal junction[J].Hepatogastroenterology,2002,49(44):419-422. [9] Feith M,Stein HJ,Siewert JR,et al. Adenocarcinoma of the esophagogastric junction:surgical therapy based on 1602 consecutive respected patients[J].Surg Oncol Clin N Am,2006,15(4):751-764. [10] Meier I,Merkel S,Papadopoulos T,et al. Adenocarcinoma of the esophagogastric junction:the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition[J].Int J Radiat Oncol Biol Phys,2008,70(5):1408-1417.DOI:10.1016/j.ijrobp.2007.08.053. [11] Ichikura T,Ogawa T,Kawabata T,et al. Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma?[J]. World J Surg,2003,27(3):334-338. [12] 王军,张辛,韩春,等.根据胸段食管癌淋巴结转移规律探讨术后预防性照射范围和适应证[J].中华放射肿瘤学杂志,2009,18(4):265-269.DOI:10.3760/cma.j.issn.1004-4221.2009.04.265. [13] 王永岗,汪良骏,张德超,等.胸段食管鳞癌淋巴结转移特点及临床意义[J].中华肿瘤杂志,2000,22(3):241-243. [14] Dresner SM,Lamb PJ,Bennett MK,et al. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction[J].Surgery,2001,129(1):103-109. [15] Hasegawa S,Yoshikawa T,Cho H,et al. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center[J].World J Surg,2009,33(1):95-103.DOI:10.1007/s00268-008-9740-4. [16] Siewert JR,Feith M,Werner M,et al. Adenocarcinoma of the esophagogastric junction:results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients[J].Ann Surg,2000,232(3):353-361. [17] Yamashita H,Katai H,Morita S,et al. Optimal extent of lymph node dissection for Siewert type Ⅱ esophagogastric junction carcinoma[J].Ann Surg,2011,254(2):274-280.DOI:10.1097/SLA.0b013e3182263911. [18] Chang JS,Lim JS,Noh SH,et al. Patterns of regional recurrence after curative D2 resection for stage Ⅲ(N3) gastric cancer:implications for postoperative radiotherapy[J].Radiother Oncol,2012,104(3):367-373.DOI:10.1016/j.radonc.2012.08.017.
2015, Vol. 24 
